Zoledronic and Basophil count increased - a phase IV clinical study of FDA data

Summary:

Basophil count increased is reported as a side effect among people who take Zoledronic (zoledronic acid), especially for people who are female, 50-59 old, have been taking the drug for < 1 month also take Kisqali, and have Breast cancer metastatic.

The phase IV clinical study analyzes which people have Basophil count increased when taking Zoledronic. It is created by eHealthMe based on reports of 29,760 people who have side effects when taking Zoledronic from the FDA, and is updated regularly.

What is Zoledronic?

Zoledronic has active ingredients of zoledronic acid. eHealthMe is studying from 29,812 Zoledronic users. Check the latest studies of Zoledronic.

What is Basophil count increased?

Basophil count increased is found to be associated with 174 drugs and 267 conditions by eHealthMe. Check the latest studies of Basophil count increased.

On Jul, 03, 2026

29,760 people reported to have side effects when taking Zoledronic.
Among them, 38 people (0.13%) have Basophil count increased.

Could Zoledronic cause Basophil count increased?

Among these 38 people:

How long have people been on Zoledronic when they have Basophil count increased? *

What is the gender of people who have Basophil count increased when taking Zoledronic? *

female: 100 %
male: 0.0 %

What is the age of people who have Basophil count increased when taking Zoledronic? *

What are other drugs people take besides Zoledronic? *

Kisqali: 30 people, 78.95%
Anastrozole: 21 people, 55.26%
Femara: 20 people, 52.63%
Fexofenadine Hydrochloride: 16 people, 42.11%
Letrozole: 8 people, 21.05%
Palbociclib: 7 people, 18.42%
Irbesartan: 4 people, 10.53%
Leuprolide Acetate: 4 people, 10.53%
Fulvestrant: 4 people, 10.53%
Gabapentin: 4 people, 10.53%

What are other side effects people have besides Basophil count increased? *

White Blood Cell Count Decreased: 35 people, 92.11%
Lymphocyte Count Decreased: 23 people, 60.53%
Pain: 22 people, 57.89%
Tumor Marker Increased: 19 people, 50.00%
Haematocrit Decreased: 18 people, 47.37%
Haemoglobin Decreased: 18 people, 47.37%
Metastases To Bone (cancer spreads to bone): 17 people, 44.74%
Mean Cell Haemoglobin Concentration Increased (more concentration of haemoglobin in a given volume of packed red blood cells): 17 people, 44.74%
Red Blood Cell Count Decreased: 17 people, 44.74%
Back Pain: 17 people, 44.74%

What are the existing conditions these people have? *

Breast Cancer Metastatic: 24 people, 63.16%
Breast Cancer: 22 people, 57.89%
Metastases To Spine (cancer spreads to spine): 16 people, 42.11%
Metastases To Liver (cancer spreads to liver): 16 people, 42.11%
Neuralgia (pain in one or more nerves): 5 people, 13.16%
Bone Disorder: 5 people, 13.16%
Spinal Cord Neoplasm (tumour of spinal cord): 1 person, 2.63%
Metastasis (spreadable cancer to other organ from origin): 1 person, 2.63%
Metastases To Bone (cancer spreads to bone): 1 person, 2.63%
Immunodeficiency Disorders: 1 person, 2.63%

* Approximation only. Some reports may have incomplete information.

Do you take Zoledronic and have Basophil count increased?

- Check whether Basophil count increased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Zoledronic:

Zoledronic (29,812 reports)

Browse all side effects of Zoledronic:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Basophil count increased:

Basophil count increased (174 drugs)

Browse all the conditions that are associated with Basophil count increased:

Basophil count increased (267 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on zoledronic acid (the active ingredients of Zoledronic) and Zoledronic (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.